Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
That was a public reply to a private msg. sorry if Zzzzzzzzzz offened anybody but all this negative BS on this board gets me boared and tired. We all know where we stand and I'm sure I'm not alone in saying that we don't need some so call newbie poster (prob. an alias) spreading more BS
G711
Zzzzzzzzzzzzzzzzz
Jim you seem to be a smart guy after all you were named as an authority by the Windsor Star do you really belive this is the same type of play as CMKX.
I just wish everyone would just relax with their interpretations
of whats going to happen and just let it play out.
JUST RELAX
G711
Here we go another brand new poster pretending to be long , only to turn into a basher , damm this S@ is getting old ENOUGH ALREADY we all know where we stand ..... time will tell
G711
Well if it was in the article in the world famous Windsor Star then by gollie it must be the truth
G711
We all know the current trend but does anyone still belive let's take a count I'm 1
G711
What you ask Continuous bashing non stop ok ok we get it
G711
Gotta feel sorry for people like you rook. I'm sure others feel the same , give it up its only money after all
G711
Thats for sure,the market never makes sense,if so it would be too easy
G711
One of my main reasons for buying was the Baker Bros. buying in and another similar co. is ALTH that they are in also
G711
NEWS DEC.11 AFTER THE CLOSE
December 11, 2006 - 4:30 PM EST
Seattle Genetics Reports Positive Phase I Clinical Trial Results with SGN-40 in Non-Hodgkin's Lymphoma and Multiple Myeloma at ASH
Seattle Genetics, Inc. (Nasdaq:SGEN) today announced positive data from a phase I trial of lead product candidate SGN-40, demonstrating that it exhibits durable objective responses and is well-tolerated in patients with non-Hodgkin's lymphoma (NHL) who have failed multiple prior therapies. Another phase I study showed SGN-40 induces antitumor activity, is well-tolerated and a maximum tolerated dose has not been reached in patients with relapsed multiple myeloma. The data were reported today at the American Society of Hematology (ASH) 48th Annual Meeting and Exposition in Orlando, Florida.
"We are focused on developing SGN-40 to its fullest potential. It is a promising agent with multiple applications in non-Hodgkin's lymphoma and other hematologic malignancies," said Clay B. Siegall, Ph.D., President and Chief Executive Officer of Seattle Genetics. "We are preparing to initiate a phase II study in aggressive non-Hodgkin's lymphoma based on the positive data from our phase I study, and are planning combination studies in non-Hodgkin's lymphoma and multiple myeloma to being in 2007."
Data Details
In a single-arm, dose-escalation study, 35 patients have been enrolled with various subtypes of NHL, including diffuse large B-cell, follicular, mantle cell, marginal zone and small lymphocytic lymphomas (abstract 695). The median number of prior therapies per patient was 3.5. Out of 31 evaluable patients, five (16%) had measurable objective responses, including one complete response ongoing after 41 weeks. Four patients achieved partial responses, three of which are ongoing with durations of 10, 18 and 31 weeks. Eight additional patients (26%) had stable disease at the end of treatment. Notably, of the five responses, three were in patients with diffuse large B-cell lymphoma, an aggressive subtype of NHL.
SGN-40 was well-tolerated using a dose-loading schedule. No dose-limiting toxicities or immunogenicity were identified and adverse events were consistent with antibody administration, including fatigue and headache.
"The results of this phase I clinical trial are encouraging," said Ranjana Advani, MD, Assistant Professor of Medicine, Stanford University Medical Center and presenting investigator of the phase I study. "Existing approved therapies for relapsed non-Hodgkin's lymphoma have limited efficacy and tolerability. The durable objective responses we observed in this trial, especially those in patients with diffuse large B-cell lymphoma who had received multiple prior therapies, support further investigation of SGN-40."
Seattle Genetics plans to initiate a single-agent phase II clinical trial of SGN-40 in patients with diffuse large B-cell lymphoma to further investigate its utility in the relapsed or refractory patient population.
In the multiple myeloma study, findings demonstrate that SGN-40 is well-tolerated up to 8 milligrams per kilogram (mg/kg) and a maximum tolerated dose has not been reached in a phase I study of 32 patients with relapsed disease (abstract 3576). Antitumor activity and B-cell depletion have been observed, providing rationale for further dose escalation. The protocol has been amended to test increased dose intensity and higher doses of SGN-40.
In preclinical studies, SGN-40 was shown to enhance the efficacy of several chemotherapeutic agents in non-Hodgkin's lymphoma cell lines, suggesting that it may be combined with conventional lymphoma treatments to improve therapeutic activity (abstract 2499). In addition, SGN-40 showed single-agent antitumor activity in preclinical models of multiple myeloma as well as enhanced activity when combined with low doses of bortezomib (Velcade(R)) (abstract 3506).
The company plans to initiate multiple trials of SGN-40 in combination with chemotherapy in hematologic malignancies in 2007.
About SGN-40
SGN-40 is a humanized monoclonal antibody that targets the CD40 antigen, which is highly expressed on most B lineage hematologic malignancies including non-Hodgkin's lymphoma, multiple myeloma and chronic lymphocytic leukemia. CD40 is also found on many types of solid tumors, including bladder, renal and ovarian cancer, and may also play a role in immunologic diseases. In addition to relapsed/refractory NHL, SGN-40 is undergoing phase I clinical trials for multiple myeloma and chronic lymphocytic leukemia.
About Seattle Genetics
Seattle Genetics is a biotechnology company developing monoclonal antibody-based therapies for the treatment of multiple types of cancer, including non-Hodgkin's lymphoma, multiple myeloma, acute myeloid leukemia and Hodgkin's disease. The company has also developed proprietary antibody-drug conjugate (ADC) technology comprised of highly potent synthetic drugs and stable linkers for attaching the drugs to monoclonal antibodies. Seattle Genetics currently has license agreements for its ADC technology with a number of leading biotechnology and pharmaceutical companies, including Genentech, Bayer, CuraGen and MedImmune. More information can be found at www.seattlegenetics.com.
Certain of the statements made in this press release are forward-looking, such as those, among others, relating to the therapeutic benefit and future advancement of SGN-40. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Factors that may cause such a difference include risks related to adverse clinical results as SGN-40 advances in clinical trials, such as patients exhibiting progressive disease or severe adverse events. More information about the risks and uncertainties faced by Seattle Genetics is contained in the company's filings with the Securities and Exchange Commission. Seattle Genetics disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Seattle Genetics
Peggy Pinkston, Corporate Communications, 425-527-4160
ppinkston@seagen.com
Source: Business Wire (December 11, 2006 - 4:30 PM EST)
News by QuoteMedia
www.quotemedia.com
Signed by me and my debt collectors
Very interesting company with plenty of insider buying going on ,not to mention the 2006 RBC Capital Markets Healthcare Conference being held at the Westin New York at Times Square Hotel in New York City. The panel will be moderated by Jason Kantor, Ph.D., Biotechnology Equity Research Analyst at RBC Capital Markets.
CDOC is my 2 week pick, check out for the DD, great story,world first 3D underwater sonar
http://www.investorshub.com/boards/board.asp?board_id=5306
REPOST OF GARY RENNIE #`s
Posted by: PowerPole
In reply to: greenspirit who wrote msg# 191273 Date:11/24/2006 2:41:02 PM
Post #of 191352
Here's Gary Rennie's email address...
And phone number at the Windsor Star...
grennie5@cogeco.ca
519-255-5777 extension 407
519-735-1681
(I'm not sure if this is his home or cell phone number)
Still more hope , Thanks John aka, jobec_a
http://archive.gulfnews.com/articles/06/08/21/10061629.html
Wessal to buy 25% stake in Sulja Bros
Dubai: Wessal international group has announced that it intends to purchase 25 per cent of Sulja Brothers in the open market. Sulja Bros Building Supplies Inc is a publicly listed company on the stock exchange in the US and specialises in the sale of building supplies. Wessal International Group's President Ahmad Khalil Al Muslamani stated that the purchase will enable Wessal International Group to lead the way in the construction and real state industry in the Gulf.
This was not out of Windsor and was not Marketwire or Newsblaze generated so it didn't come from Petar!
Thank you for going out of your way ,however I doubt very much those SCUM*%@* at the paper will print a followup ,the media just plain S__ks
G711
EXCELLENT POST FROM ... jerseyboy,
Thank You
FOR ALL TRUE LONGS WHO ARE STILL CONFIDENT IN SLJB:
I think it would be worthwhile to read what I have to say. Much as I'm sure it has been for you, this day has been hard for me, as I really can't afford to lose what I have invested here. When faced with adversity, however, instead of screaming, crying, threatening and/or insulting people, I try to get to the root of a problem and fix it, or at least understand it.
In that light, I spoke with both Leslie and Dave at the Harrow location this afternoon. Both are long-time employees of the company who have known Petar for 6 and 15 years, respectively. The consensus seems to be that Petar is just an average, hardworking guy with a wife and three kids who shuns the limelight and does not want to be a public figure. What I heard specific to our situation is that the company's lawyers recommended that Petar hold off on releasing the financials until the Windsor Star article was addressed. The Star was at the Harrow location with Petar this afternoon, and the impression I got was that some kind of follow-up article may be printed in the near future. I think that Petar may be being directed by legal counsel to hold the financials until the Star issues that follow-up article. I'm not totally clear on the rationale for this, but that seems to be the case.
In any event, Petar also directed Leslie to give out his cell phone number, as he wanted people to be able to speak directly with him about the situation. I now have that and also have his home number and two work numbers. I will, if the lack of issuance of the financials persists, keep calling him and/or Leslie and Dave on a daily basis until I reach him and he (or they) can explain to me what the situation is, why it exists, and when we will see financials issued. I am convinced that this is not a scam, but is just a situation created by a man who does not like what he is doing, and, as a result, who is not executing certain of this current responsibilities properly. However, by virtue of taking the position, when he does not follow through on promises made, he owes me and the rest of us as well as the investment community an explanation as to why.
I sensed a lot of anger and resignation today as I read the board. Resignation will get us nowhere, and well-placed anger can be channeled in a civil way toward helping our CEO solve our mutual problem; in other words, holding him accountable for his promises and helping him to do the right thing. We have a problem to solve, so let's turn our attention to solving it.
Yikes ,I hate to say it but it looks like ,Thunderbird wine followed by White Castle's in Coney Island, I hope im wrong
G711
COUNT ME IN FOR THE PARTY , IM LONG GOING FOR A RIDE ON THE SHIP LETS ALL HOPE IT DOSENT SINK
G711
THE WEBSITE IS FINE
http://suljabros.com/news.html
CDOC..... Creede did you check out the IHUB page I started in March when this was at .45 ,
http://www.investorshub.com/boards/board.asp?board_id=5306
Is there a way of checking how many reads on a board ?
Thanks, G711
Its supposed to be when you least expect it and catch the unbelievers off guard, so be prepared to be surprised,hey JJ you there
your a mess
CDOC climbs to a new high today ,port security exciting tech..
http://www.investorshub.com/boards/board.asp?board_id=5306
New all time high we closed at $1.50 could be the start now that the Vegas show is complete .% wise the jump in the volume is tremendous, with a little moee volume and the low float we maybe headed way north. BWTFDIK nobodys outhere.
G711
Well a little action today ,maybe the show in Vegas has gotten some intrest in CDOC
Im a big fan as well as others to be buying when everone else is selling what a great time to be in SLJB when all the naysayers are dumping , great time to be getting "ALLIN" as in....... well you know the rest
BOO Im here along with a few others
Hey Fazzy buying a penny stock as your first investment is like riding a Harley at age one before you can even walk....did you ask anyone for advice,maybe a mutual fund would have been a better choice not that SLJB is a bad choice but you need to get your feet wet before jumping in the Atlantic ocean,nevertheless
Good Luck
G711
Your welcome just trying to do my part for the Ihub family
CDOC shareprice..$1.40 o/s....22,172656 cap...$31,041,718 its at 52 wk high and cutting edge tech. for Port Security,worlds first 3 D sonar,real company . check out this link
http://www.investorshub.com/boards/board.asp?board_id=5306
Thanks to Allinone for this great post if anyone needs to tell a family member or a friend about SLJB then this is what they need to print out, it says it all
G711
Posted by: allinone
In reply to: None Date:10/21/2006 8:36:53 AM
Post #of 126663
Good morning everyone! Hope some got some sleep! "Your Welcome" is the response I will give to the many who have PM'd me re the DD that was provided. Just my part of the puzzle being put together by many here. Now to the many who want to know what my price prediction is and the time frame. I will take a few things into consideration when I put this pricing plan together. First the huge short position currently held from the old days of LFWK and second the validation with the uplisting that the audited financials will give to the company!! And last but certainly not the least, the 2006-2007 projected revenue. Anyone heard of a pink sheet with audited financials? Anyone heard of a pink sheet stock with projected next year earnings of possibly $750 million??? Just as I thought, NO!!! By researching other PINK CRAP that has run to $4.00 and above on NO REVENUE, NO FUTURE PROJECTED REVENUES, etc. etc. etc., I see this stock possibly running to the $7.00 area initially while everyone tries to get on the boat and the shorts try to cover. Remember their start point was in the .40 range about a year ago. If the projected revenues for 2006-2007 do in fact get upped to $750 million, due to the recently announced cement deal, then the valuation of the stock will be around $12.00 in one year. The one year time frame is because they will have to show the actual revenues meeting the projected revenues in actual financials. I think in the short run, within 3 months we will see a swing of present levels to the $7.00 area settling back into the $4.00 to $5.00 range. I think many more contracts will be announced shortly and the Balance Sheet with assets from UAE will continue to support that SLJB is no longer a pink sheet stock, nor an OTC BB stock but in fact a NASDAQ stock, as commented by the CEO of the company! Remember, when they are listed on the NASDAQ, many institutional buyers MUST buy the stock due to their indexed portfolio's of the NASDAQ. Many of you here have only dealt with penny stocks and some play them successfully. This time your pennies are going to turn into life changing dollars, imho. You can sell for penny's if you wish but IMHO you will be sitting back with a gun to your head in about 4 months going "WHY DID I SELL THIS EARLY"! Again, thanks for the kind words folks and for those who have always believed and supported the company, CONGRATULATIONS!!!! jmho
I had got in at .005 near Thanksgiving was that guy on this site also i cant recall ,i noticed him caused he was all over another stock that ran up cant think of that symbol,after 40 the burbon cells kick in,lol
Hey JIM you still holding ,check the date,lol
Posted by: Jim Bishop
In reply to: Rager who wrote msg# 3840 Date:11/22/2005 11:46:32 AM
Post #of 126266
LOL if you're talking about me, I'm still long 200k this turd.
I see the shorts and evil market makers are taking a break today...dick all for volume, Denny needs to put out more news with little info.
Hey H O G this is where I found it last year under LFWK this guy had like a 20 min video graph explanation on it cant seem to get on the site though does anyone know this guy,he had the site up last thanksgiving
http://mysite.verizon.net/vzepone6/